About: Azithromycin, a broad‐spectrum macrolide antibiotic, is being investigated in patients with COVID‐19. A population pharmacokinetic model was implemented to predict lung, intracellular poly/mononuclear cell (PBM/PML), and alveolar macrophage (AM) concentrations using published data and compared against preclinical EC90 for SARS‐CoV‐2. The final model described the data reported in 8 publications adequately. Consistent with its known properties, concentrations were higher in AM and PBM/PML, followed by lung tissue, and lowest systemically. Simulated PBM/PML concentrations exceeded EC90 following the first dose and for approximately 14 days following 500 mg QD for 3 days or 500 mg QD for 1 day/250 mg QD on days 2‐5, 10 days following a single 1000 mg dose, and for more than 20 days with 500 mg QD for 10 days. AM concentrations exceeded the IC90 for more than 20 days for all regimens. These data will better inform optimization of dosing regimens for azithromycin clinical trials.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : covidontheweb.inria.fr associated with source document(s)

AttributesValues
type
value
  • Azithromycin, a broad‐spectrum macrolide antibiotic, is being investigated in patients with COVID‐19. A population pharmacokinetic model was implemented to predict lung, intracellular poly/mononuclear cell (PBM/PML), and alveolar macrophage (AM) concentrations using published data and compared against preclinical EC90 for SARS‐CoV‐2. The final model described the data reported in 8 publications adequately. Consistent with its known properties, concentrations were higher in AM and PBM/PML, followed by lung tissue, and lowest systemically. Simulated PBM/PML concentrations exceeded EC90 following the first dose and for approximately 14 days following 500 mg QD for 3 days or 500 mg QD for 1 day/250 mg QD on days 2‐5, 10 days following a single 1000 mg dose, and for more than 20 days with 500 mg QD for 10 days. AM concentrations exceeded the IC90 for more than 20 days for all regimens. These data will better inform optimization of dosing regimens for azithromycin clinical trials.
Subject
  • Macrophages
  • Zoonoses
  • Immune system
  • COVID-19
  • Pharmacy
  • Cell biology
  • Phagocytes
  • Respiratory physiology
  • Macrolide antibiotics
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software